239 related articles for article (PubMed ID: 1908726)
1. Graft versus host disease prophylaxis today.
Martelli MF; Aversa F
Bone Marrow Transplant; 1991; 7 Suppl 2():112-6. PubMed ID: 1908726
[No Abstract] [Full Text] [Related]
2. Perspectives in the prevention and treatment of acute graft versus host disease.
Herve P
Bone Marrow Transplant; 1991; 7 Suppl 2():117-9. PubMed ID: 1715225
[No Abstract] [Full Text] [Related]
3. Bone marrow transplantation for severe aplastic anaemia: cost/benefit of increased immunosuppression.
Gordon-Smith EC
Bone Marrow Transplant; 1991; 7 Suppl 2():103-5. PubMed ID: 1908725
[No Abstract] [Full Text] [Related]
4. Graft-versus-leukemia without graft-versus-host disease: an elusive goal of bone marrow transplantation.
Champlin R
Semin Hematol; 1992 Jul; 29(3 Suppl 2):46-52. PubMed ID: 1509294
[No Abstract] [Full Text] [Related]
5. Treatment of acute graft versus host disease with a murine monoclonal antibody to the IL-2 receptor.
Tiley C; Powles R; Teo CP; Treleaven J; Findlay M; Hewetson M
Bone Marrow Transplant; 1991; 7 Suppl 2():151. PubMed ID: 1652326
[No Abstract] [Full Text] [Related]
6. Allogeneic bone marrow transplantation without graft-v-host disease: true tolerance of graft against the host through depletion of donor T lymphocytes pregrafting in malignant and nonmalignant disorders.
Slavin S; Or R; Naparstek E; Weiss L; Mumcuoglu M; Weshler Z; Brautbar H; Cividalli G; Glikson M; Hale G
Transplant Proc; 1987 Feb; 19(1 Pt 3):2614-5. PubMed ID: 3274569
[No Abstract] [Full Text] [Related]
7. Depletion of bone marrow T-lymphocytes with an anti-CD5 monoclonal immunotoxin (ST-1 immunotoxin): effective prophylaxis for graft-versus-host disease.
Antin JH; Bierer BE; Smith BR; Guinan EC; Provost MM; Ferrara J; Macklis RM; Tarbell NJ; Blythman H; Bouloux C
Prog Clin Biol Res; 1990; 333():207-15. PubMed ID: 1689852
[No Abstract] [Full Text] [Related]
8. T-cell-depleted autologous marrow fails to prevent acute graft-versus-host disease after allogeneic marrow transplantation for lymphoblastic lymphoma.
Przepiorka D; Giralt S; Huh YO; Andreeff M; Luna M; Reading C; Thomas M; Champlin RE
Transplant Proc; 1992 Dec; 24(6):2906-7. PubMed ID: 1465994
[No Abstract] [Full Text] [Related]
9. Graft-versus-leukemia activity after T-cell depletion using counterflow centrifugation.
de Witte T; Preijers F; Schattenberg A
Bone Marrow Transplant; 1990 Jul; 6 Suppl 1():103-5. PubMed ID: 2202463
[No Abstract] [Full Text] [Related]
10. [T-cell depletion today: pros and cons].
Martelli MF; Aversa F
Haematologica; 1989 Oct; 74(5 Suppl):405-17. PubMed ID: 2512224
[No Abstract] [Full Text] [Related]
11. T-cell depletion in unrelated bone marrow transplantation.
Tricot G
Semin Hematol; 1992 Apr; 29(2 Suppl 1):26-31; discussion 31-2. PubMed ID: 1615342
[No Abstract] [Full Text] [Related]
12. Effector cells of graft-versus-host disease, host resistance, and the graft-versus-leukemia effect: summary of a workshop on bone marrow transplantation.
Ringdén O; Deeg HJ; Beschorner W; Slavin S
Transplant Proc; 1987 Feb; 19(1 Pt 3):2758-61. PubMed ID: 3547953
[No Abstract] [Full Text] [Related]
13. New approaches for the prevention of rejection and graft-vs.-host disease in clinical bone marrow transplantation.
Slavin S; Or R; Naparstek E; Cividalli G; Weshler Z; Weiss L; Mumcuoglu M; Engelhard D; Aker M; Pollack A
Isr J Med Sci; 1986; 22(3-4):264-7. PubMed ID: 3528046
[TBL] [Abstract][Full Text] [Related]
14. Graft versus host disease.
Gordon-Smith EC
Folia Haematol Int Mag Klin Morphol Blutforsch; 1989; 116(3-4):413-9. PubMed ID: 2480283
[No Abstract] [Full Text] [Related]
15. Antibody and pre- plus post-transplant prednisone treatments support T cell-depleted stem cell engraftment without drug-induced morbidity.
D'Costa S; Hurwitz JL
Bone Marrow Transplant; 2002 Apr; 29(7):553-6. PubMed ID: 11979302
[TBL] [Abstract][Full Text] [Related]
16. Anti LFA1 monoclonal antibody for the prevention of graft rejection after T cell-depleted HLA-matched bone marrow transplantation for leukemia in adults.
Maraninchi D; Mawas C; Stoppa AM; Gaspard MH; Marit G; Van Ekthoven A; Reiffers J; Olive D; Hirn M; Delaage M
Bone Marrow Transplant; 1989 Mar; 4(2):147-50. PubMed ID: 2650783
[TBL] [Abstract][Full Text] [Related]
17. XomaZyme-CD5 immunotoxin in conjunction with partial T cell depletion for prevention of graft rejection and graft-versus-host disease after bone marrow transplantation from matched unrelated donors.
Koehler M; Hurwitz CA; Krance RA; Coustan-Smith E; Williams LL; Santana V; Ribeiro RC; Brenner MK; Heslop HE
Bone Marrow Transplant; 1994 May; 13(5):571-5. PubMed ID: 7519937
[TBL] [Abstract][Full Text] [Related]
18. The use of monoclonal antibodies in graft versus host disease prevention.
Brenner MK; Grob JP; Prentice HG
Haematologia (Budap); 1986; 19(3):167-76. PubMed ID: 3536685
[TBL] [Abstract][Full Text] [Related]
19. Marrow transplantation for the treatment of acute leukemia using HL-A-identical siblings.
Buckner CD; Clift RA; Fefer A; Lerner KG; Neiman PE; Storb R; Thomas ED
Transplant Proc; 1974 Dec; 6(4):365-6. PubMed ID: 4612892
[No Abstract] [Full Text] [Related]
20. [Prevention of graft versus host disease by in vitro depletion of T lymphocytes with monoclonal antibodies (Campath-1) in patients undergoing bone marrow transplantation].
Iriondo A; Richard C; Hermosa V; Conde E; Garijo J; Cuadrado MA; Bello C; Muruzábal MJ; Pérez-Encinas M; Zubizarreta A
Med Clin (Barc); 1988 Oct; 91(13):488-92. PubMed ID: 3067007
[No Abstract] [Full Text] [Related]
[Next] [New Search]
